<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457690</url>
  </required_header>
  <id_info>
    <org_study_id>2010.634</org_study_id>
    <nct_id>NCT01457690</nct_id>
  </id_info>
  <brief_title>Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention</brief_title>
  <acronym>VEDROP</acronym>
  <official_title>Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the kinetics of intestinal absorption of vitamin E water-soluble form from the
      classical lipid-soluble form in a population of patients with intestinal malabsorption
      (hypocholesterolemias family by retention of chylomicrons).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement the area under the curve of absorption of vitamin E according to its dosage form (fat-soluble versus water-soluble) in the beginning of each treatment period. versus water-soluble) in the beginning of each treatment period.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum (membranes erythrocytic) of vitamin E at the beginning and after each treatment.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of serum (membranes erythrocytic) of vitamin E at the beginning and after each treatment. Search for a correlation between the rates in adipose tissue and those in the membrane of erythrocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of tissue (subcutaneous adipose tissue) of vitamin E at the beginning and after each treatment.</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of tissue (subcutaneous adipose tissue) of vitamin E at the beginning and after each treatment. Search for a correlation between the rates in adipose tissue and those in the membrane of erythrocytes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hypobetalipoproteinemias</condition>
  <arm_group>
    <arm_group_label>Tocofersolan: Vitamin E water-soluble</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocopherol alpha: Vitamin E conventional fat-soluble form</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocofersolan</intervention_name>
    <description>Administration of a daily dose of vitamin E for 4 months:50 IU/kg</description>
    <arm_group_label>Tocofersolan: Vitamin E water-soluble</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocopherol alpha</intervention_name>
    <description>Administration of a daily dose of vitamin E for 4 months:50 IU/kg</description>
    <arm_group_label>Tocopherol alpha: Vitamin E conventional fat-soluble form</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocofersolan and tocopherol alpha</intervention_name>
    <description>Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)</description>
    <arm_group_label>volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient suffering from familial hypocholesterolemia by retention of chylomicrons

          -  Systematically followed in the department of Gastroenterology and Paediatric Nutrition
             in Women Mother Child's Hospital or in the endocrinology department of GHE (Louis
             Pradel Hospital);

          -  During treatment with oral vitamin E;

          -  over the age of 3 years and weighing over 16 kg at the time of inclusion

          -  For which there is a signed informed consent from the patient or parents / guardians
             in the case of a minor patient, and benefit from social security coverage.

        Exclusion Criteria:

          -  Patient with encephalopathy

          -  Hypersensitivity to the active substance or the excipients of Vedrop

          -  A suspected allergy to local anaesthetics (including xylocaine)

          -  Patients who may not be compliant to treatment (psychiatric);

          -  In case of refusal to participate in the study from the patient and / or parents or
             legal guardian;

          -  Patients unable to consent (if patients with encephalopathy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel PERETTI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Femme Mere Enfant, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Femme Mere Enfant-Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <last_update_submitted>November 12, 2015</last_update_submitted>
  <last_update_submitted_qc>November 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin E pegylated</keyword>
  <keyword>chylomicron retention</keyword>
  <keyword>Familial Hypocholesterolemia</keyword>
  <keyword>Hypobetalipoproteinemias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypobetalipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

